Abstract 3,4-Methylenedioxymethamphetamine (MDMA) is an illicit phenethylamine ingested for entactogenic and euphoric effects. Although blood is more commonly submitted for forensic analysis, previous human MDMA pharmacokinetics research focused on plasma data; no direct blood-plasma comparisons were drawn. Blood and plasma specimens from 50 healthy adult volunteers (33 males, 17 females, 36 AfricanAmerican) who ingested recreational 1.0 and 1.6 mg/kg MDMA doses were quantified for MDMA and metabolites 4-hydroxy-3-methoxymethamphetamine (HMMA), 3,4-methylenedioxyamphetamine (MDA), and 4-hydroxy-3-methoxyamphetamine (HMA) by two-dimensional gas chromatography-mass spectrometry. Specimens were collected up to 3 h post-dose and evaluated for maximum concentration (C max ), first detection time (t first ), time of C max (t max ), and 3-h area under the curve (AUC 0-3 h ); as well as blood metabolite ratios and blood/plasma ratios. Median blood MDMA and MDA C max were significantly greater (p <0.0005) than in plasma, but HMMA was significantly less (p <0.0005). HMA was detected in few blood specimens, at low concentrations. Nonlinear pharmacokinetics were not observed for MDMA or MDA in this absorptive phase, but HMMA C max and AUC 0-3 h were similar for both doses despite the 1.6-fold dose difference. Blood MDA/ MDMA and MDA/HMMA significantly increased (p <0.0001) over the 3-h time course, and HMMA/MDMA significantly decreased (p <0.0001). Blood MDMA C max was significantly greater in females (p =0.010) after the low dose only. Low-dose HMMA AUC 0-3 h was significantly decreased in females' blood and plasma (p =0.027) and in African-Americans' plasma (p =0.035). These data provide valuable insight into MDMA blood-plasma relationships for forensic interpretation and evidence of sex-and race-based differential metabolism and risk profiles.
Introduction

3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is an illicit amphetamine derivative ingested orally for its
Electronic supplementary material The online version of this article (doi:10.1007/s00216-013-7468-y) contains supplementary material, which is available to authorized users. entactogenic, stimulant, and hallucinogenic properties [1] [2] [3] [4] [5] . In 2010, 0.9 million people took MDMA for the first time in the USA [6] ; worldwide, 10-28 million people ages have taken the drug. MDMA was found in 0.09 % of nighttime drivers in the 2007 US National Roadside Survey [5] .
There are two primary phase I MDMA metabolic pathways. The first is O-demethylenation (mainly mediated by CYP2D6) to 3,4-dihydroxymethamphetamine (HHMA), followed by Omethylation to 4-hydroxy-3-methoxymethamphetamine (HMMA). The second is N-demethylation (CYP1A2) to 3,4-methylenedioxyamphetamine (MDA), followed by Odemethylenation to intermediate 3,4-dihydroxyamphetamine and O-methylation to 4-hydroxy-3-methoxyamphetamine (HMA) [7, 8] .
Administered at recreational doses in human experimental laboratory studies, MDMA increases heart rate and blood pressure, subjective energy level, closeness to others, "high," and causes perceptual changes [9, 10] . Subjective effects peak 1-2 h post-administration [9, 11] . As a stimulant, some driving performance aspects may improve, but others (e.g., speed adaptation ability) may be impaired [12] . Although blood is a forensically relevant matrix for MDMA and metabolite evaluation, previous clinical and preclinical studies primarily focused on plasma [7, 10, 11, [13] [14] [15] .
We developed a sensitive two-dimensional gas chromatography-mass spectrometry (2D-GCMS) method with cryotrapping for simultaneously quantifying MDMA, HMMA, MDA, HMA, and 3,4-methylenedioxyethylamphetamine (MDEA) in whole blood. We employed this 2D-GCMS method for studying MDMA and metabolite whole blood pharmacokinetics and correlated MDMA and metabolite blood and plasma concentrations for the first time after controlled MDMA administration. These data will be useful for forensic toxicologists interpreting MDMA blood test results. , and p -hydroxymethamphetamine (pholedrine) from Sigma (St. Louis, MO). Isopropanol, sodium acetate, and ethyl acetate were acquired from Sigma; GCgrade n-heptane, dibasic potassium phosphate, acetic acid, and HPLC-grade methanol were from Fisher Scientific (Fair Lawn, NJ). Hydrochloric acid, sodium hydroxide, ammonium hydroxide, and monobasic potassium phosphate were obtained from JT Baker (Phillipsburg, NJ), triethylamine (>99.5 % purity) from Thermo Scientific (Rockford, IL), and heptafluorobutyric acid anhydride (HFAA) from Regis Technologies, Inc. (Morton Grove, IL). Styre Screen TM 6 mL 50 mg DBX solid-phase extraction (SPE) columns were purchased from United Chemical Technologies (Bristol, PA). Blank human plasma and blood were obtained from the National Institutes of Health blood bank.
Materials and methods
Reagents
Participants
Fifty healthy adult participants provided written informed consent for this National Institute on Drug Abuse Intramural Research Program Institutional Review Board-approved research (Table 1) . Participants underwent comprehensive medical and psychological examinations, including medical and drug histories, as previously described [16] . Eligibility requirements included intake of ≥5 lifetime MDMA tablets (self-report, ≥1 tablet within the past month), ages 18-40 years, and medically acceptable birth control or abstinence (females) throughout the study. Serum pregnancy tests were administered at screening, and urine pregnancy tests preceded each dose administered to females. Exclusion criteria included nursing or pregnant; current medical condition or history of neurologic illness; axis I psychiatric diagnosis other than nicotine, cannabis, or MDMA abuse or dependence; ingestion of a CYP2D6 or CYP3A4 inhibitor or CYP3A4 inducer in the 30 days prior to MDMA administration; abnormal cardiovascular parameters; and serum transaminase greater than three times normal.
Study procedures
Participants resided on a secure clinical research unit up to 23 days (continuous stay encompassing all dosing sessions or separate stays separated by ≥1 week). Admission to the residential unit was ≥12 h prior to MDMA dosing. Participants ingested placebo (0 mg/kg), low (1.0 mg/kg), or high (1.6 mg/kg) dose MDMA (Lipomed, Arlesheim, Switzerland) in a randomized, counterbalanced, and double-blind manner. Active drug was administered as the hydrochloride salt; placebo contained lactose. For safety, a maximum 150-mg dose limit was enforced in six participants whose weight exceeded 93.75 kg.
Blood collection
Blood was collected in sodium heparin (green top) vacutainers at −0.25, 0.5, 1.0, 1.5, 2.0, 2.5, and 3 h after dosing and placed on ice immediately after collection. Plasma was collected after centrifuging blood at 2,000×g , 4°C for 10 min within 2 h after collection. Blood was collected for only 3 h due to a 450-mL maximum total blood collection limit per participant as required by the ethical committee. Extended plasma pharmacokinetics (up to 143 h) from this study were previously published [7] . Blood and plasma were stored frozen (−20°C) until analysis.
Plasma analysis MDMA, MDA, HMMA, HMA, and MDEA concentrations were quantified with a validated, modified 2D-GCMS method [17] . Briefly, 1 mL plasma was fortified with internal standard (MDMA-d5, MDA-d5, and pholedrine) and hydrolyzed with 1 mL 0.5 mol/L HCl at 100°C for 40 min. After cooling, 1 mL of 0.1 mol/L phosphate buffer (pH 6.0) and 50 μL of 10 mol/L sodium hydroxide were added. After centrifugation, supernatant was decanted onto preconditioned polymeric Styre Screen DBX SPE columns. Columns were washed, dried, and extracts eluted with ethyl acetate/isopropanol/ammonium hydroxide (90:6:4, v/v/v). Methanolic HCl (15 μL, 0.12 mol/ L) was added prior to evaporation. Residues were reconstituted with 100 μL of 0.1 mol/L triethylamine in heptane and incubated with 10 μL HFAA (derivatizing reagent) at 60°C for 30 min. Phosphate buffer (200 μL, pH 7.4) was added to cooled samples and the aqueous phase discarded. Samples were injected onto an Agilent 6890 GC-5973 mass selective detector instrument equipped with microfluidic Deans' switch and flame ionization detector. Instrument parameters were previously reported by Kolbrich et al. [17] . Linear ranges were 2.5-400 μg/L (MDMA and HMMA), 2.5-100 μg/L (HMA), and 1-100 μg/L (MDA). Extraction efficiencies were ≥85 %, inter-and intra-assay imprecision coefficients of variation (N =20) were ≤6.7 %, and analytical bias was between 14.4 and 7.2 % of target.
Blood analysis
MDMA, MDA, HMMA, HMA, and MDEA were quantified in blood by the plasma method described above with minor modifications. Extraction was performed with 1 mol/L pH 4.5 acetate buffer and reconstitution in 0.2 mol/L triethylamine in heptane.
Method validation was performed to reflect guidelines recently established by the Scientific Working Group for Forensic Toxicology (SWGTOX) [18] and included determining dynamic linear ranges for all compounds, limits of detection and quantification (LOQ), recoveries, accuracy and imprecision, endogenous and exogenous interference studies, carryover, stability, and dilution integrity. Parameters were determined with low, medium, and high quality control (QC) samples (Table 2 ). Detailed validation procedures and results are presented in text and Table S1 of the Electronic Supplementary Material, which provides specific calibration concentrations for each analyte.
Data analysis
Statistical analyses were performed with IBM® SPSS® Statistics 19.0.0 for Windows. Data displayed non-normal distribution by visual inspection and Kolmogorov-Smirnov tests; thus, nonparametric analyses were utilized. Observed time of first detection (t first ), maximum concentration (C max ), time of maximum concentration (t max ), and 3-h area under the curve (AUC 0-3 h , calculated by linear trapezoidal method) were compared with the Wilcoxon signed-ranks test. Betweengroup sex and race comparisons were performed with the Mann-Whitney U test. Because only two participants identified as unknown/Hispanic and/or mixed-race/ethnicity (insufficient for additional categories), these individuals were included in a group with white participants. To avoid ambiguity, cases where no analyte was detected were excluded from t first and t max calculations. Blood/plasma ratios were calculated only when analytes were quantifiable in both matrices. Low and high dose blood/plasma ratios, overall and by time, were compared with the Wilcoxon signed-ranks test. Analyte ratios (MDA/MDMA, HMMA/MDMA, and MDA/HMMA) also were evaluated with Wilcoxon signed-ranks test, and temporal differences were evaluated by independent samples median test. Linear least-squares plasma vs. blood concentration (MDMA, MDA, HMMA) regressions were evaluated in GraphPad Prism 5.02 (GraphPad Software Inc.).
Results
Participants
Fifty volunteers (33 males, 17 females) participated; 41 completed all three sessions. Demographic and amphetamines use history are presented in Table 1 .
Blood method
The optimized blood MDMA and metabolite assay was achieved by modifying the plasma method to optimize the pH for extraction and triethylamine concentration for derivatization. Extraction at pH (6.0) utilized for plasma analyses revealed poor HMA extraction efficiency with non-detectable HMA at 3.0 μg/L; >25.2 % HMA extraction efficiency was achieved with pH 4.5 buffer [19] . Validation data are presented in Table 2 and in the Electronic Supplementary Material.
Blood and plasma specimens
Blood (144 after placebo, 321 after low, and 297 after highdose MDMA) and plasma (145 after placebo, 321 after low, and 300 after high-dose MDMA) specimens were analyzed for MDMA, HMMA, MDA, and HMA. There were 757 (144 placebo, 316 low, 297 high) concurrently collected blood and plasma specimens. Specimens were analyzed until there were three consecutive negative specimens, resulting in fewer total placebo analyses. Rigorous plasma pharmacokinetic analysis (17 participants, up to 143 h post- dose) was previously published [7] . Blood was collected up to 3 h post-dose. Figure 1 depicts blood time courses for MDMA and metabolites. Metabolite HMMA concentrations were similar after the two doses, but MDMA and MDA 2D-GC two-dimensional gas chromatography, MS mass spectrometry, MDMA 3,4-methylenedioxymethamphetamine, MDA 3,4-methylenedioxyamphetamine, HMMA 4-hydroxy-3-methoxymethamphetamine, HMA 4-hydroxy-3-methoxyamphetamine, MDEA 3,4-methylenedioxyethylamphetamine concentrations were dose dependent. HMA was only detected in four blood specimens.
MDMA and MDA
Median blood MDMA and MDA C max were significantly greater than in plasma (p <0.0005, Table 3 ). Overall median MDMA blood and plasma C max achieved after the high dose were 1.7 and 1.6 times those after the low dose, reflecting the 1.6-fold difference in MDMA administered. Median MDA 3 h observed C max in both blood and plasma also was 1.6-fold higher after the high dose. Median t max occurred at 2.5 h for MDMA and 3.0 h for MDA, consistent with the demethylation process requiring additional time to peak. Similarly, t first was nonsignificantly earlier (0.5 h) for the parent compound than the metabolite (1.0 h), and MDA after the low, but not high, dose revealed a significantly earlier t first (p =0.002) in blood than plasma. Median MDMA AUC 0-3 h were 1.7-and 1.6-fold higher in blood and plasma after the high than low dose, respectively, consistent with C max . Median MDA AUC 0-3 h high vs. low dose ratios were lower (1.5 and 1.4 for blood and plasma, respectively).
Median MDMA blood C max was significantly greater in females than males (p =0.010) after the low dose only. Plasma C max and AUC 0-3 h did not differ significantly by sex for MDMA or MDA, nor did blood MDA C max or AUC 0-3 h . No racial differences in MDMA or MDA C max or AUC 0-3 h were observed.
Two participants (16 and 24) had consistent and quantifiable MDMA from baseline throughout the placebo session (Fig. S1 , Electronic Supplementary Material). Self-reported last-consumed MDMAwas 2 days (16) and 16-20 h (24) prior to first specimen collection. MDA was detected in both individuals' plasma and in blood for participant 16 only. Participant 11 chewed and expectorated the high-dose capsule. No MDMA, MDA, or HMA was detected in his blood or plasma. HMMA was still positive from a previous dose, and concentrations remained within ±16 and ±9 % of baseline for blood and plasma, respectively. This session was excluded from t first , C max , and t max calculations.
HMMA and HMA Blood HMMA C max was significantly less than in plasma (p <0.0005) at both MDMA doses (Table 3) . HMMA concentrations were not linear with dose, achieving median highdose C max and AUC 0-3 h 1.0 and 1.1 times those of the low dose (Table 3 and Fig. 1a) . t max and t first did not differ between doses or matrices. Few specimens were positive for HMA (blood, n =4/618; plasma, n =41/621). HMA only slightly exceeded the 2.5-μg/L LOQ when positive (C max 3.1, 2.6 μg/L [low, high blood]; 3.2, 3.5 μg/L [low, high plasma]). The trend (p =0.070) for slightly lower HMA concentrations in blood vs. plasma after the low dose became significant (p =0.012) at the high dose. There were too few positive HMA specimens to statistically compare doses or matrices for t first or t max .
The only significant sex difference observed was with HMMA concentrations after the low MDMA dose, which showed lower AUC 0-3 h in females than males (p =0.027, blood and plasma). Also, for the low dose only, plasma HMMA AUC 0-3 h was significantly lower (p =0.035) in African-American participants. No blood matrix or highdose racial differences were observed.
MDEA
The MDMA capsules administered in the study did not contain MDEA, and no MDEA was detected in blood or plasma. (Fig. 2) . In this primarily absorptive phase, only MDA displayed a significantly greater overall blood/plasma ratio after the high than the low dose (p <0.0005). Blood MDMA and MDA concentrations were always greater than plasma (ratio >1); HMMA blood concentrations were always less than those of plasma. Despite substantial inter-subject variability, ratios were relatively consistent over time, particularly MDMA. Linear least-square regression equations for bloodplasma concentration relationships were y =0.9287x −5.280 (MDMA), y =0.5214x +0.7891/y =0.6570x −0.1834 (MDA low/high), and y =1.342x +3.094 (HMMA), with respective R 2 =0.9512, 0.5889/0.7409, and 0.8964 (Fig. S2 , Electronic Supplementary Material). All correlations were significant (p <0.0001). There was only one paired HMA specimen (high dose, t =3 h, blood/plasma=0.72).
Analyte ratios
Blood MDA/MDMA (Fig. 3a) and MDA/HMMA (Fig. 3c ) ratios significantly increased (p <0.0001) over the 3-h time course, whereas HMMA/MDMA ratios significantly decreased overall (p <0.0001), but were relatively stable after the first hour post-dose (Fig. 3b) . Low vs. high-dose time course slopes were not significantly different for MDA/ MDMA, MDA/HMMA, or HMMA/MDMA. Beginning at 1.0 h, HMMA/MDMA was significantly greater (p <0.005) after the low than the high dose, and after 1.5 h, MDA/ HMMA was significantly greater (p <0.005) after the high dose. MDA in blood was almost 20-fold lower than blood MDMA. Overall MDA/MDMA, MDA/HMMA, and HMMA/MDMA ratios all displayed significant dose differences (p <0.0005), although mean low vs. high dose MDA/ MDMA differed by only 8.5 % (0.052 vs. 0.047). Thus, despite statistical significance, this difference was not clinically significant. Mean MDA/MDMA low vs. high dose was 26.7 % greater (1.46 vs. 1.15), and mean MDA/HMMA low vs. high was 21.3 % lower (0.088 vs. 0.111).
Discussion
We established and validated a sensitive, specific 2D-GCMS method for simultaneously quantifying MDMA, MDA, HMMA, HMA, and MDEA in blood and utilized this method to analyze specimens after controlled MDMA administration. We believe this to be valuable analytically novel information in that it contains, to our knowledge, the first published whole blood method for simultaneous quantification of MDMA and its metabolites HMMA, MDA, and HMA, as well as MDEA [14, [20] [21] [22] [23] [24] [25] [26] [27] . MDMA and MDA are weak bases (pK a approximately 9.9 [28] and 9.67 [29] , respectively); as are probably HMA and HMMA, based on their amine groups. Thus, these analytes were more effectively protonated (ionized) at the lower extraction pH, allowing more consistent cation exchange SPE column functionality. Doubling the triethylamine concentration in the reconstitution solvent also improved HMA quantification. Extraction efficiencies from blood were substantially diminished compared to our previously published plasma results [17] . We attempted to improve recovery by testing QC specimens extracted at pH 6 (n =3) and after protein precipitation with ice-cold acetonitrile after hydrolysis (n =3), neither condition improved extraction efficiency. We were able to achieve desired sensitivity with acceptable analytical performance despite low analyte recoveries. The recent publications of the SWGTOX guidelines on method validation were followed. These new comprehensive guidelines demonstrate proper validation procedures in a concise and simplified manner. This information combining both analysis and interpretation of blood MDMA following controlled MDMA administration will benefit the field.
We present, for the first time, in vivo human blood vs. plasma relationships for MDMA and metabolites MDA, HMMA, and HMA. We also examined metabolite ratios in blood and directly compared sex and racial differences in MDMA pharmacokinetics. This study was limited by the 3-h post-dose blood collection window imposed by a total blood collection limit of 450 mL/participant over the entire study. This prevented extended blood pharmacokinetic analysis. In cases where t max was reported as 3 h, the true t max could have been later; C max were observed 3 h data. Another limitation was long-term storage prior to analysis. Although stored frozen at −20°C in the dark, blood and some plasma specimens were not analyzed until 1-7 years after collection. MDMA and MDA were determined to be stable frozen ≥17 weeks in serum and 5 weeks in blood [30, 31] , but longer-term MDMA and metabolite stabilities are not fully characterized.
To our knowledge, blood-plasma relationships were previously determined in only two in vitro studies [31, 32] . MDMA and MDA concentrations were significantly (p <0.0005) higher in blood than plasma (Table 3 and Fig. 3) . Garrett et al. [31] documented similar red blood cell (RBC)-plasma coefficients for MDMA and MDA (1.48 and 1.45, respectively), corroborating our findings. Values are higher than the blood/plasma ratios we determined, possibly because reported results were partition coefficients for separated RBCs vs. plasma rather than whole blood vs. plasma concentrations. Plasma protein binding was reported to be 34-40 % for both compounds. In contrast, Belhadj-Tahar et al. [32] reported the (hematocrit normalized) RBC vs. whole blood partition coefficient for MDA (MDMA not reported) as 30 %, the free fraction 27 %, and the plasma protein-bound fraction 71 %.
We found significant dose-dependent differences in MDA blood/plasma ratios and concentration correlations (Fig. 2 and Fig. S2 , Electronic Supplementary Material). Based on previous findings [31] , which showed MDA and MDMA plasma protein binding was not dose dependent, the relative increase may relate more to RBC affinity than to plasma protein binding. Taken together, these results suggest that higher concentrations may gradually exceed RBC binding capacity, allowing more free drug to partition into plasma. Correlation coefficients were relatively high for MDMA (0.9512) and HMMA (R 2 = 0.8964) and somewhat lower for MDA (>0.58). This suggests greater inter-subject variability in MDA blood-plasma partitioning than for MDMA and HMMA, possibly contributing to these findings.
To our knowledge, no HMMA or HMA partition coefficients were reported to date, but our results (blood-plasma ratio <1 and significantly lower blood C max ) indicate HMMA partitions more readily into plasma. The significant HMMA blood/plasma ratio dose difference observed at 1.5 h (Fig. 2) represents a minor fluctuation likely caused by inter-subject variability and appears to lack clinical significance. HMA is a relatively minor metabolite, with concentrations never exceeding 3.5 μg/L during the 3-h time course, even after the high dose. The single paired-positive HMA result (0.72 blood/ plasma ratio) agreed with the slightly lower C max in blood, but is insufficient to draw conclusions.
The two participants positive for MDMA, HMMA, and MDA after the placebo capsule (Fig. S1 , Electronic Supplementary Material) self-reported ingesting an average of eight MDMA pills/month in the prior 3 months (Table 1) . Our closed research unit prevented drug intake within 12 h prior to controlled MDMA/placebo administration, and these participants self-reported last MDMA ingestion >16 h prior to the placebo dose. Although blood and plasma concentrations observed here did not result from controlled administration and should be interpreted with caution, they offer blood information from a longer post-dose window. The data collected from these individuals corroborates the MDMA and HMMA findings from controlled administration; blood concentrations were higher and lower than in plasma, respectively. MDA blood and plasma concentrations were near the LOQ throughout these sessions. Previous studies reported MDMA, HMMA, and MDA plasma t 1/2 5.9-11.8 [7, 10, 11, 33] , 9.8-10.4 [7, 33] , and 9.3-17.7 h [7, 10, 33] , respectively, with substantial t 1/2 intersubject variability [7] . Farre et al. [10] documented longer MDMA and MDA t 1/2 24-48 h after MDMA administration than in the first 24 h (8.8 vs. 7.0 and 14.1 vs. 12.8 h, respectively), indicating a longer secondary distribution and excretion phase.
Blood MDA/MDMA (p < 0.0005) and MDA/HMMA (p <0.01) ratios significantly increased after dosing, while HMMA/MDMA significantly decreased (p <0.01), reaching a plateau after approximately 1.5 h (Fig. 3) .The statistically significant (p =0.010) low-high MDA/MDMA dose difference observed at 3 h was minor and not clinically significant. Although initially unexpected that HMMA/MDMA decreased during the 3-h post-dose, this agrees with previous plasma findings [7] showing greater initial ratios that decreased for the first few hours post-dose as MDMA increased. HMMA/MDMA gradually increased during the 10-40-h post-dose window. Previous studies showed MDMA inhibits its own metabolism [7, 10, 11] through CYP2D6 inhibition of the primary pathway to HMMA. This inhibition occurs within 2 h [11] . By 4 h after 1.5 mg/kg MDMA, CYP1A2 activity increased 20-40 % [34] . We hypothesize this process likely explains the patterns observed. As the major HMMA metabolic pathway was inhibited, the MDA pathway increased, thereby increasing MDA ratios. For the same reason, HMMA/ MDMA was greater-and MDA/HMMA less-in the low dose relative to the high. Greater MDMA doses more rapidly inhibited the 2D6 enzyme.
Prior research [7] indicated median plasma t max >3 h for MDA (7.1 h [low and high]) and HMA (11.0 h [low] and 12.0 h [high]). Our blood results appear to emulate those findings, since C max did not appear within the 3 h window. Similar observed t max , occurring prior to 3 h, suggests true MDMA and HMMA C max are reported. AUC 0-3 h represents the MDMA absorption window, so our results matched the 1.6-fold dose difference. The nonlinear plasma pharmacokinetics we previously observed [7] appear to extend from inhibited metabolism and decreased clearance, causing lasting elevated concentrations that impacted the later time course. Our HMMA results for both matrices corroborate those previously described, showing equal C max and slightly elevated (1.1 high/low ratio) AUC 0-3 h . The 1.3 previously reported plasma AUC ∞ ratio reflects longer-term metabolism inhibition. MDA patterns were similar, linearly reflecting the dose difference for this 3-h window despite showing greater differences in extended C max and AUC ∞ . HMA was detected in few blood specimens, corroborating a longer formation time. Extended plasma pharmacokinetics revealed that 79 and 100 % of 17 participants' plasma specimens were HMA positive 23 h after the low and high dose, respectively [7] .
Between-subjects sex and race C max and AUC 0-3 h comparisons revealed significant differences after the low dose only, agreeing with our previous findings [7] . The greater blood MDMA C max in females (p =0.010) did not significantly alter AUC 0-3 h . We did not observe the previously reported significantly increased female plasma MDA C max or AUC, but our decreased female HMMA low-dose AUC 0-3 h in whole blood and plasma supports previous plasma results. Females exhibit a stronger MDMA-induced CYP2D6 inhibition profile than males [35] , possibly explaining decreased MDMA clearance after the lower dose only. We hypothesize the higher 1.6 mg/kg dose caused substantial enough enzyme inhibition that sex did not display the differential effect observed after the low dose.
Previously, we had too few participants to examine racial differences. In this study, our sample was large enough that for the first time, and we were able to directly compare and show a significant MDMA pharmacokinetic difference between African-American and white/Hispanic or mixed-race individuals. We observed a significantly lower (p =0.035) plasma HMMA AUC 0-3 h in African-American participants after the low dose, suggesting increased toxicity risk due to decreased metabolism. Although this was the only statistically significant racial difference observed, it is possible that the diminished post-dose time course did not allow racial metabolic differences to fully manifest. As noted with sex differences, the observation that only the low dose showed a differential racial effect may indicate that the 1.6-mg/kg dose caused substantial enough enzyme inhibition that race did not display the differential effect observed after the low dose.
Genetic polymorphisms, particularly in the CYP2D6 enzyme, influence pharmacokinetic profiles of MDMA and its metabolites. A recent study by Pardo-Lozano et al. [36] demonstrated that individuals carrying two functional alleles (FA) for CYP2D6 produce significantly higher HMMA plasma concentrations relative to carriers with one FA. It is likely that the patterns observed in plasma would be reflected in blood, i.e., higher blood HMMA concentrations (and possibly increased MDMA clearance) would be observed in cases of extensive metabolizers. However, we believe that MDMA inhibition of its own metabolism is a more important factor in explaining our findings, as also reported by Yubero-Lahoz et al. [35] . We do not anticipate that this would alter blood vs. plasma findings.
In summary, we present for the first time blood MDMA and metabolites pharmacokinetics after controlled oral MDMA administration. The MDMA and metabolite blood/ plasma correlation data presented here are highly relevant and, as far as we are aware, the first available in the literature. This is the first direct comparison between paired blood and plasma specimens and the first evidence of racial differences in MDMA metabolism. The racial and sex differences we observed warrant further investigation in order to determine the extent of greater toxicity risk in females and AfricanAmericans. These controlled MDMA administration data provide valuable information for interpretation of clinical and forensic data. This information fills a critical knowledge gap of MDMA and metabolite analysis and concentrations in blood; previous analytical procedures and results focused almost entirely on plasma. Our blood data and matrix comparisons will be beneficial for interpreting forensic cases, given the prior focus on plasma in the published literature.
